Reducing the abuse potential of controlled substances

Pharmaceutical Medicine

Volumn 24, Issue 1, 2010, Pages 21-36

  Coleman, John J ^a   Schuster, Charles R ^b,c   DuPont, Robert L ^d  

^a Prescription Drug Research Center   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CRS Associates LLC   (United States)

^d Institute for Behavior and Health   (United States)

Author keywords

Drug abuse; Drug overdose; Food and Drug Administration; Legislation; Opioid abuse; Opioid analgesics, abuse; Opioid analgesics, overdose; Opioid analgesics, therapeutic use; Opioid receptor antagonists, therapeutic use; Pharmaceutical industry

Indexed keywords

ACUROX; ANALGESIC AGENT; ANTIDIARRHEAL AGENT; ATROPINE PLUS DIPHENOXYLATE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; COCAINE; DEXTROPROPOXYPHENE; DIAMORPHINE; DRONABINOL; EMBEDA; EXALGO; FENTANYL; HYDROMORPHONE; LISDEXAMFETAMINE; METHYLPHENIDATE; MORPHINE; MOTOFEN; NALOXONE; NALTREXONE; NYCYNTA; ONSOLIS; OPIATE; OROS; ORPHAN DRUG; OXYCODONE; OXYNAL; OXYTREX; PREGABALIN; TAPENTADOL; UNCLASSIFIED DRUG;

CONTROL STRATEGY; DRUG ABUSE; DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SUBSTANCE ABUSE; TECHNOLOGY;

EID: 77949576154     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/BF03256795     Document Type: Review

References (95)

1. Fingerhut LA, Griffiths C,Wilkins K. Drug poisoning: trends and current status. US, England & Wales, Canada. PowerPoint slide programme. Atlanta, (GA): Centers for Disease Control, 2004 [online]. Available from URL: www.cdc.gov/ nchs/ppt/injury/drug-poisoning.ppt [Accessed 2010 Feb 19]
2. Paulozzi LJ, Xi Y. Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmacoepidemiol Drug Saf 2008 Oct; 17 (10): 997-1005
3. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2008 National Survey on Drug Use and Health: national findings NSDUH series H-36, HHS publication no. SMA 09-4434) [online]. Available from URL: http://www.oas.samhsa.gov/nsduh/ 2k8nsduh/2k8Results.cfm [Accessed 2010 Feb 19]
4. Wick JY. Drug-abuse deterrent formulations. Consult Pharm 2009 May; 24 (5): 356-62, 65
5. Wisniewski AM, Purdy CH, Blondell RD. The epidemiologic association between opioid prescribing, non-medical use, and emergency department visits. J Addict Dis 2008; 27 (1): 1-11
6. Dasgupta N, Kramer ED, Zalman MA, et al. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006 Apr 28; 82 (2): 135-142
7. Joranson DE. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283: 1710-1714
8. Zacny J, Bigelow G, Compton B, et al. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: position statement. J Drug Alcohol Depend 2003; 69: 215-232
9. Gilson AM, Ryan KM, Joranson DE, et al. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004; 28 (2): 176-188
10. Novak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained- release opioid analgesics: a revisit. Pain Med 2004 Mar; 5 (1): 59-65
11. Office of National Drug Control Policy. The economic costs of drug abuse in the United States 1992-1998. Washington, DC: USGPO, 2001
12. Schmidt C. Experts worry about chilling effect of federal regulations on treating pain. J Natl Cancer Inst 2005 Apr 20; 97 (8): 554-555
13. Jung B, Reidenberg M. The risk of action by the Drug Enforcement Administration against physicians prescribing opioids for pain. J Pain Med 2006; 7 (4): 353-357
14. Goldenbaum DM, Christopher M, Gallagher RM, et al. Physicians charged with opioid analgesic-prescribing offenses. J Pain Med 2008; 9 (6): 737-747
15. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: premarketing risk assessment, 2005 [online]. Available from URL: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ ucm126958.pdf [Accessed 2010 Feb 8]
16. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: development and use of risk minimization action plans, 2005 [online]. Available from URL: http://www.fda.gov/downloads/ RegulatoryInformation/Guidances/UCM126830.pdf [Accessed 2010 Feb 08]
17. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment, 2005 [online]. Available from URL: http://www. fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf [Accessed 2010 Feb 08]
18. US Department of Health & Human Services, US Food and Drug Administration. FDA's role in preventing prescription drug abuse: statement of Robert J. Meyer, M.D., Director, Office of Drug Evaluation II, Center for Drug Evaluation and Research, Food and Drug Administration before the House Committee on Government Reform, U.S. House of Representatives September 13, 2005 [online]. Available from URL: http://www.fda.gov/ NewsEvents/Testimony/ ucm112718.htm [Accessed 2010 Feb 25]
19. Federal Register, Vol 73, Issue 60. Notices: identification of drug and biological products deemed to have risk evaluation and mitigation strategies for purposes of the Food and Drug Administration Amendments Act of 2007, Department of Health and Human Services. Washington, DC: GPO, 2008: 16313
20. Food and Drug Administration, Office of Special Health Issues. Opioid analgesic and risk evaluation and mitigation strategies (REMS) stakeholder meeting, May 2009 [online]. Available from URL: http://google2.fda.gov/search?q= cache: i-Ehho1ABf8J:www.fda.gov/downloads/Drugs/DrugSafety/Informationby DrugClass/UCM188796.pdf+class-wide+REMS&client=FDAgov&site=FDA gov&lr=&proxystylesheet=FDAgov&output=xml-no-dtd&ie= UTF-8&access =p&oe=ISO-8859-8861 [Accessed 2009 Dec 27]
21. Justia US Laws. Controlled Substances Act/Code of Federal Regulations: part 1302, labeling and packaging requirements for controlled substances, stat. 21CFR1302 (1970) [online]: Available from URL: http://law.justia.com/us/ cfr/title21/21-9.0.1.1.3.html [Accessed 2010 Feb 25]
22. Title 21, United States Code, y 801, et seq. Congressional findings and declarations: controlled substances (1970) [online]. Available from URL: http://vlex. com/vid/declarations-controlled-substances-19200580 [Accessed 2010 Feb 25]
23. Food and Drug Administration. Approved risk evaluation and mitigation strategies, 2009 Sep 16 [online]. Available from URL: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm111350.htm [Accessed 2010 Feb 08]
24. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: national findings NSDUH series H-34, DHHS publication no. SMA 08-4343) [online]. Available from URL: http://www.oas.samhsa.gov/ NSDUH/2k7NSDUH/2k7results.cfm [Accessed 2010 Feb 19]
25. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Trends in nonmedical use of prescription pain relievers: 2002-2007 [online]. Available from URL: http://www.oas.samhsa.gov/2k9/ painRelievers/nonmedicalTrends.htm#fn1 [Accessed 2010 Feb 8]
26. May EL, Jacobson AE. The Committee on Problems of Drug Dependence: a legacy of the National Academy of Sciences. A historical account. Drug Alcohol Depend 1989; 23: 183-218
27. College on Problems of DrugDependence. Conference program, 2005 [online]. Available from URL: http://www.cpdd.vcu.edu/Media/Index/ImpactConf Prog.pdf [Accessed 2009 Dec]
28. Acker CJ. Addiction and the laboratory: the work of the National Research Council's Committee on drug addiction, 1928-1939. Isis 1995; 86 (2): 167-193
29. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009 Jul; 10 Suppl. 2: S124-33
30. Wick YW. Drug-abuse deterrent formulations. Consultant Pharmacist 2009; 24 (5): 356-365
31. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Exp Opin Investig Drugs 2009Mar; 18 (3): 255-263
32. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009 July; 84 (7): 593-601
33. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep 2008; 10: 11-18
34. Purdue Pharma L.P. Research & Development. FDA Advisory Committee briefing document on NDA 22-272 (reformulated OxyContin (R) tablets) [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCom mittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugs AdvisoryCommittee/UCM183205.pdf [Accessed 2010 Feb 08]
35. Spencer TJ. Adult ADHD: diversion and misuse of medication. CNS Spectrums 2008; 13 (10 Suppl. 15): 9-13
36. Committee on Energy and Commerce - 107th Congress House Hearings. OxyContin: its use and abuse (serial no. 107-54) 2001 Aug 28 [online]. Available from URL: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname= 107-house-hearings&docid=f:75754.wais [Accessed 2010 Feb 10]
37. U.S. Senate Committee on Health, Education, Labor, and Pensions. Hearing to examine the effects of the painkiller OxyContin 2002 [online]. Available from URL: http://frwebgate.access.gpo.gov/cgi-bin/getpage.cgi?dbname=2002- record&page=S673&position=all [Accessed 2010 Feb 10]
38. Crosse M. U.S. General Accountability Office Report to Congressional Requesters - prescription drugs: OxyContin abuse and diversion and efforts to address the problem (Report #GAO-04-110). USGPO, 2003 [online]. Available from URL: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname= gao&docid=f:d04110.pdf [Accessed 2010 Feb 10]
39. Drug Enforcement Administration. Action plan to prevent the diversion and abuse of OxyContin(R), 2001 [online]. Available from URL: http://www. deadiversion.usdoj.gov/drugs-concern/oxycodone/abuse-oxy.htm [Accessed 2009 Sep 24]
40. Meier B. Restrictions are upheld for executives in OxyContin case [online]. Available from URL: http://www.nytimes.com/2009/01/24/business/ 24pharma. html?scp=1&sq=Goldenheim&st=nyt [Accessed 2009 Sep 20]
41. Durect Corporation. The ORADUR- Sustained release gel cap technology [online]. Available from URL: http://www.durect.com/wt/durect/page- name/oradur [Accessed 2009 Sep 20]
42. Perrone M. Associated Press: FDA panel backs reformulated OxyContin pill [online]. Available from URL: http://www.google.com/hostednews/ap/article/ ALeqM5jcoA0TaqKh08Sld66ZNXjtlst3TAD9ATU1LG1 [Accessed 2009 Sep 25]
43. U.S. Department of Justice, Drug Enforcement Administration. Technical amendment to listing in schedule III of approved drug products containing tetrahydrocannabinols: notice of proposed rulemaking. Federal Register Doc. No. DEA-308P 2007;72:54226-54230 [online]. Available from URL: http://frwebgate4. access.gpo.gov/cgi-bin/PDFgate.cgi?WAISdocID=1035234 24861+1+2+0&WAISaction= retrieve [Accessed 2010 Feb 10]
44. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol). J Psychoact Drugs 1998 Apr-Jun; 30 (2): 187-196
45. U.S. Department of Justice, Drug Enforcement Administration. Rescheduling of dronabinol product in the Marinol formulation from C-II to C-III of the CSA: final rule. Federal Register Doc. 99-1683 1999; 64: 35928-35930 [online]. Available from URL: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi? dbname=1999-register&docid=99-16833-filed.pdf [Accessed 2010 Feb 4]
46. Eddy NB. The National Research Council involvement in the opium problem: 1928-1971. Washington, DC: National Academy of Sciences, 1973
47. Coleman JJ, Bensinger PB, Gold MS, et al. Can drug design inhibit abuse? J Psychoact Drugs 2005 Dec; 37 (4): 343-362
48. BaumC,Hsu JP,Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 1987; 102 (4): 426-429
49. Fudala PJ, Johnson RE. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006 Jun; 83 Suppl. 1: S40-7
50. Reckitt Benckiser Pharmaceuticals. Suboxone prescribing information (label), 2006 [online]. Available from URL: http://www.suboxone.com/pdfs/ Suboxone PI.pdf [Accessed 2009 Sep 23]
51. Wolters Kluwer Health Inc. Drug facts and comparisons: 2009. St Louis (MO): Wolters Kluwer Health, 2008
52. Acura Pharmaceuticals, Inc. Company website [online]. Available from URL: http://acurapharm.com/ [Accessed 2009 Sep 22]
53. Parasrampuria DA, Schoedel KA, Schuller R, et al. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007 Oct; 27 (5): 459-467
54. McCabe SE, Teter CJ, Boyd CJ. Medical use, Illicit use and diversion of prescription stimulant medication. J Psychoact Drugs 2006 Mar; 38 (1): 43-56
55. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006 Mar; 163 (3): 387-395
56. Volkow ND. Stimulant medications: how tominimize their reinforcing effects? Am J Psychiatry 2006 Mar; 163 (3): 359-361
57. PR Newswire Association LLC. Neuromed announces exalgo (hydromorphone HCl) extended-release tablet [online]. Available from URL: http:// www.drugs.com/clinical-trials/neuromed-announces-exalgo-hydromorphonehcl- extended-release-tab-6899.html [Accessed 2009 Sep 20]
58. Food and Drug Administration, Center for Drug Evaluation and Research. Consultation on Exalgo (hydromorphone HCL) ER tablets [online]. Available from URL: http://www.fda.gov/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/ucm18 3033.htm [Accessed 2009 Sep 24]
59. Reuters. US advisers back plan to monitor Covidien pain drug [online]. Available from URL: http://www.reuters.com/article/euRegulatoryNews/ idUSN2315490920090923 [Accessed 2009 Sep 24]
60. Janssen Pharmaceutica LP. Package insert Duragesic C-II (fentanyl transdermal system). Titusville (NJ): Janssen Pharmaceutica LP, 2003
61. Substance Abuse and Mental Health Services Administration; Office of Applied Studies; DAWN series D-24; DHHS publication no. (SMA) 03-3780. Emergency department trends from the drug abuse warning network: final estimates 1995-2002. Rockville (MD):U.S. Government PrintingOffice, 2003
62. Mathias R. Rate and duration of drug activity play major roles in drug abuse, addiction, and treatment. NIDA Notes 1997; 12 (2): 1-6
63. Volkow ND, Ding Y-S, Fowler JS, et al. Cocaine addiction: hypothesis derived from imaging studies with PET. J Addict Dis 1996; 15: 55-71
64. Brookoff D. Abuse potential of various opioid medications. J Gen Intern Med 1993 Dec; 8 (12): 688-690
65. Food and Drug Administration. Decision letter by Steven K. Galson, M.D., M.P.H., Acting Director, Center for Drug Evaluation and Research, providing FDA's scientific analysis used to deny four Citizens Petitions regarding fentanyl transdermal patches, 2005 [online]. Available from URL: http:// www.fda.gov/ohrms/dockets/dockets/06p0290/06p-0290-cp00001-03-Exhibit- 02-vol1.pdf [Accessed 2010 Feb 18]
66. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network (DAWN)- detailed tables: drug-related emergency department visits for 2004-2008 [online]. Available from URL: http://dawninfo. samhsa.gov/data/ [Accessed 2010 Feb 18]
67. Drug Topics Resource Guide. Top 200 drugs: a five-year compilation (2004- 2008). Montvale (NJ); Advanstar Medical Economics Communications, 2009
68. Inciardi JA, Surratt HL, Stivers Y, et al. FDA approvals of generic drugs: impact on the diversion of opioid analgesics with a potential for abuse. J Opioid Manage 2009 Mar-Apr; 5 (2): 81-87
69. Cicero TJ, Inciardi JA, Surratt H. Trends in the use and abuse of branded and generic extended release oxycodone and fentanyl products in the United States. Drug Alcohol Depend 2007 Dec 1; 91 (2-3): 115-120
70. Centers for Disease Control and Prevention. Nonpharmaceutical fentanyl-related deaths:multiple states, Apr 2005-Mar 2007 [online].Available fromURL: http:// www.cdc.gov/mmwr/preview/mmwrhtml/mm5729a1.htm [Accessed 2009 Dec 26]
71. Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations, 2009 [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm [Accessed 2009 Dec 26]
72. Chemicool online chemistry dictionary. Definition of prodrug [online]. Available from URL: http://www.chemicool.com/definition/prodrug.html [Accessed 2009 Sep 25]
73. Shire Pharmaceuticals. Shire and New River Pharmaceuticals announce FDA approval of the first and only stimulant prodrug VYVANSE (TM) (lisdexamfetamine dimesylate) as a novel treatment for ADHD [online]. Available from URL: http://www.highbeam.com/DocPrint.aspx?DocId= 1G1:159717214 [Accessed 2007 Sep 22]
74. Shire Pharmaceuticals. Lisdexamfetamine approved for treating ADHD, 2007 [online].Available fromURL: http://www.highbeam.com/doc/1G1-163421887. html [Accessed 2010 Feb 10]
75. HighBeam Research. KemPharm, Inc. expands prodrug pipeline with candidate for treatment of pain and closes series B financing, 2009 [online]. Available from URL: http://www.highbeam.com/doc/1G1-207861046.html [Accessed 2009 Sep 22]
76. Greene P. Drug Use Data Analyst, Office of Surveillance and Epidemiology, Food and Drug Administration, Center for Drug Evaluation and Research, Drug utilization trends for selected immediate-release and extended-release opioid pain products (Appendix 2, Table 1), 2009 [online]. Available from URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM1 83034.pdf [Accessed 2010 Feb 10]
77. Substance Abuse and Mental Health Services Administration, Office of Applied Studies Drug Abuse Warning Network, 2006: National estimates of drugrelated emergency department visits. DAWN series D-30, DHHS publication no. (SMA) 08-4339. Rockville (MD): U.S. Government Printing Office, 2008
78. Food and Drug Administration. Electronic Orange book: approved drug products with therapeutic equivalence evaluations. US Department of Health and Human Services, 2008 [online]. Available from URL: http://www. accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm [Accessed 2009 Dec 26]
79. Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluation and Research. Remoxy: in vivo abuse resistance studies, 2008 [online]. Available from URL: www.fda.gov/ohrms/dockets/ac/08/ slides/2008-4395s1-03-FDA-Ji.ppt [Accessed 2009 Dec 28]
80. Durect Corporation.ORADURTechnology. 2009 [online].Available fromURL: http://www.durect.com/wt/durect/page-name/oradur [Accessed 2009 Dec 28]
81. Durect Corporation. ORADUR- controlled oral delivery technology, 2008 [online]. Available fromURL: http://www.durect.com/pdf/oradur-brochure- 20080107.pdf [Accessed 2009 Dec]
82. Schuster CR. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 2006; 83 Suppl. 1: S8-14
83. McColl S, Sellers EM. Research design strategies to evaluate the impact of formulations on abuse liability. Drug Alcohol Depend 2006 Jun; 83 Suppl. 1: S52-62
84. McCormick CG. Regulatory challenges for new formulations of controlled substances in today's environment. Drug AlcoholDepend 2006 Jun; 83 Suppl. 1: S63-7
85. King Pharmaceuticals, Inc. Full prescribing information for Embeda, 2009 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda- docs/label/2009/022321s000lbl.pdf [Accessed 2009 Sep 25]
86. Anabolic Steroid Control Act. Pub. L. No.101-647 yy 1901-1907 (1990) [online]. Available from URL: http://thomas.loc.gov/cgi-bin/query/F?c101:3:./ temp/~c101sO5RVH:e197740 [Accessed 2010 Mar 4]
87. United Nations. Convention on psychotropic substances, 1971 [online]. Available from URL: http://www.incb.org/pdf/e/conv/convention-1971-en.pdf [Accessed 2009 Dec 28]
88. Controlled Substances Act, 21 USC 801a [online]. Available from URL: http:// frwebgate6.access.gpo.gov/cgi-bin/TEXTgate.cgi?WAISdocID=037087340548 +0+1+0&WAISaction=retrieve [Accessed 2009 Dec 29]
89. Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS), 2009 [online]. Available from URL: http://www.fda.gov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm111350.htm [Accessed 2010 Jan 29]
90. Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, et al. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis 2008; 3: 33
91. Reaves ND. A model of effective health policy: the 1983 Orphan Drug Act. J Health Soc Policy 2003; 17 (4): 61-71
92. Li JS, Eisenstein EL, Grabowski HG, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 2007 Feb 7; 297 (5): 480-488
93. NDCHealth. Top 200 drugs for 2003 by U.S. sales [online]. Available from URL: http://www.ndchealth.com/press-center/uspharmaindustrydata/top200 drugs-03.htm [Accessed 2004 Nov 20]
94. Gorodetzky CW, Grudzinskas C. Involving the pharmaceutical and biotech communities in medication development for substance abuse. Pharmacol Ther 2005 Oct; 108 (1): 109-118
95. Hohenstein K. Just what the doctor ordered: theHarrison anti-narcotic act, the supreme court, and the federal regulation of medical practice, 1915-1919. J Supreme Court History 2001 Nov; 26 (3): 231-256